PE05742002A1 - Humanized antibodies that recognize beta amyloid the peptide - Google Patents

Humanized antibodies that recognize beta amyloid the peptide

Info

Publication number
PE05742002A1
PE05742002A1 PE0012222001A PE0012222001A PE05742002A1 PE 05742002 A1 PE05742002 A1 PE 05742002A1 PE 0012222001 A PE0012222001 A PE 0012222001A PE 0012222001 A PE0012222001 A PE 0012222001A PE 05742002 A1 PE05742002 A1 PE 05742002A1
Authority
PE
Peru
Prior art keywords
residue
light chain
sequence
variable
region
Prior art date
Application number
PE0012222001A
Other languages
Spanish (es)
Inventor
Guriq Basi
Jose Saldanha
Ted Yednock
Original Assignee
Wyeth Corp
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US25189200P priority Critical
Application filed by Wyeth Corp, Elan Pharma Int Ltd filed Critical Wyeth Corp
Publication of PE05742002A1 publication Critical patent/PE05742002A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22953834&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE05742002(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0007Nervous system antigens; Prions
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711Alzheimer's disease; Amyloid plaque core protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55572Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77Internalization into the cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Abstract

SE REFIERE A UNA CADENA LIGERA O PESADA DE INMUNOGLOBULINA HUMANIZADA COMPRENDIENDO REGIONES DE DETERMINACION DE COMPLEMENTARIEDAD DE REGION VARIABLE (CDRs) A PARTIR DE LA SECUENCIA DE REGION VARIABLE DE LA CADENA LIGERA DE LA INMUNOGLOBULINA 3D6 COMO SE PRESENTA EN SEQ ID NO:2 Y COMPRENDIENDO REGIONES DE CUADRO VARIABLE DE UNA SECUENCIA DE CADENA LIGERA DE INMUNOGLOBULINA DEL RECEPTOR HUMANO, SIEMPRE Y CUANDO AL MENOS UN RESIDUO DE CUADRO SEA SUSTITUIDO CON EL CORRESPONDIENTE RESIDUO AMINOACIDO DE LA SECUENCIA DE REGION VARIABLE DE LA CADENA LIGERA DE LA 3D6 DONDE EL RESIDUO DE CUADRO SE SELECCIONA DE : a) UN RESIDUO QUE DE MANERA NO COVALENTE SE UNE AL ANTIGENO DIRECTAMENTE; Refers to a light chain or immunoglobulin heavy HUMANIZED UNDERSTANDING determining regions complementarity variable region (CDRs) from SEQUENCE REGION VARIABLE light chain immunoglobulin 3D6 as presented in SEQ ID NO: 2 AND UNDERSTANDING REGIONS OF TABLE VARIABLE OF A SEQUENCE light chain immunoglobulin human receptor, provided that at least one residue PICTURE be replaced with the corresponding amino acid residue SEQUENCE OF REGION VARIABLE LIGHT CHAIN ​​OF 3D6 WHERE THE WASTE OF TABLE is selected from: a) WHAT a WASTE noncovalently directly binds to antigen; b) UN RESIDUO ADYACENTE A UNA CDR; b) adjacent a CDR RESIDUE; c) UN RESIDUO QUE INTERACTUA CON LA CDR Y d) UN RESIDUO QUE PARTICIPA EN LA INTERFASE VL-VH. c) a residue interacts with CDR and d) a residue participating in the VL-VH INTERFASE. SE REFIERE TAMBIEN A AGENTES MEJORADOS QUE INCLUYEN ANTICUERPOS HUMANIZADOS PARA EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS A LOS DEPOSITOS AMILOIDEOS DE Aß EN EL CEREBRO COMO LA ENFERMEDAD DE ALZHEIMER ALSO it REFERS TO AGENTS INCLUDING IMPROVED humanized antibodies for the treatment of diseases associated with amyloid Aß DEPOSITS IN THE BRAIN AS ALZHEIMER'S DISEASE
PE0012222001A 2000-12-06 2001-12-05 Humanized antibodies that recognize beta amyloid the peptide PE05742002A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US25189200P true 2000-12-06 2000-12-06

Publications (1)

Publication Number Publication Date
PE05742002A1 true PE05742002A1 (en) 2002-07-02

Family

ID=22953834

Family Applications (1)

Application Number Title Priority Date Filing Date
PE0012222001A PE05742002A1 (en) 2000-12-06 2001-12-05 Humanized antibodies that recognize beta amyloid the peptide

Country Status (39)

Country Link
US (2) US7189819B2 (en)
EP (2) EP2045267A3 (en)
JP (6) JP4166569B2 (en)
KR (2) KR100996936B1 (en)
CN (4) CN100448893C (en)
AR (1) AR035402A1 (en)
AT (1) AT414719T (en)
AU (2) AU2002225921B8 (en)
BG (1) BG66292B1 (en)
BR (1) BR0115978A (en)
CA (1) CA2430772C (en)
CY (1) CY1108740T1 (en)
CZ (1) CZ20031601A3 (en)
DE (1) DE60136651D1 (en)
DK (1) DK1358213T3 (en)
EA (2) EA010469B1 (en)
EC (1) ECSP034685A (en)
EE (1) EE05309B1 (en)
ES (1) ES2317953T3 (en)
GE (1) GEP20084339B (en)
HK (1) HK1070904A1 (en)
HR (1) HRP20030547A8 (en)
HU (1) HU229681B1 (en)
IL (2) IL156030D0 (en)
IS (1) IS2620B (en)
MX (1) MXPA03005048A (en)
MY (2) MY163362A (en)
NO (1) NO339290B1 (en)
NZ (3) NZ526813A (en)
PE (1) PE05742002A1 (en)
PL (1) PL211761B1 (en)
PT (1) PT1358213E (en)
SI (1) SI1358213T1 (en)
SK (1) SK288209B6 (en)
TW (1) TWI255272B (en)
UA (1) UA87093C2 (en)
UY (1) UY27062A1 (en)
WO (1) WO2002046237A2 (en)
ZA (1) ZA200305169B (en)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913745B1 (en) * 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
US8697082B2 (en) * 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
DE1257584T1 (en) 2000-02-24 2003-05-28 Univ St Louis uncheck the amyloid-beta peptide humanized antibodies,
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
PE05742002A1 (en) * 2000-12-06 2002-07-02 Wyeth Corp Humanized antibodies that recognize beta amyloid the peptide
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
AU2002257162A1 (en) * 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
WO2002088306A2 (en) * 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
EP1420032B2 (en) 2001-08-03 2015-12-16 Medical & Biological Laboratories Co., Ltd. Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody
US7771722B2 (en) 2001-08-17 2010-08-10 Eli Lilly And Company Assay method for alzheimer's disease
CA2452104A1 (en) * 2001-08-17 2003-02-27 Eli Lilly And Company Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
AR038568A1 (en) 2002-02-20 2005-01-19 Hoffmann La Roche anti-beta antibodies and their use
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
GB2392792B (en) * 2002-09-07 2004-12-15 Matsushita Electric Ind Co Ltd Improvements to television and radio programme control
US20080014194A1 (en) * 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en) * 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
MX2007001679A (en) 2004-08-09 2007-05-23 Elan Pharm Inc Prevention and treatment of synucleinopathic and amyloidogenic disease.
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β (1-42) oligomers, processes for their preparation and their use
NZ567324A (en) 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
WO2004071408A2 (en) 2003-02-10 2004-08-26 Applied Molecular Evolution, Inc. Aβ BINDING MOLECULES
US20050129695A1 (en) * 2003-03-28 2005-06-16 Marc Mercken Anti-amyloid antibodies, compositions, methods and uses
JP5930573B2 (en) 2007-03-01 2016-06-15 プロビオドルグ エージー A new use of glutaminyl cyclase inhibitors
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
EP1480041A1 (en) * 2003-05-22 2004-11-24 Innogenetics N.V. Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
TWI306458B (en) * 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
KR101321876B1 (en) * 2003-10-27 2013-10-28 와이어쓰 엘엘씨 Removal of high molecular weight aggregates using hydroxyapatite chromatography
US8147833B2 (en) * 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8092801B2 (en) * 2007-02-23 2012-01-10 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
EP2118300B1 (en) 2007-02-23 2015-05-27 Prothena Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
PT2118300E (en) 2007-02-23 2015-09-22 Univ California Prevention and treatment of synucleinopathic and amyloidogenic disease
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
WO2005047324A2 (en) * 2003-11-10 2005-05-26 Schering Corp Interleukin-10 antibodies
BRPI0507856A (en) * 2004-02-23 2007-07-10 Lilly Co Eli Pharmaceutical composition and process for preparing the Abeta antibody
US20050225165A1 (en) * 2004-04-13 2005-10-13 Naik Sanjeev M Brake by-wire control system
AT500483B1 (en) * 2004-07-13 2006-01-15 Mattner Frank Dr Set for prevention or treatment of Alzheimer's disease
KR101068289B1 (en) 2004-07-30 2011-09-28 리나트 뉴로사이언스 코퍼레이션 Antibodies directed against amyloid-beta peptide and methods using same
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI384069B (en) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals Production of polypeptides
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
CA2582194A1 (en) * 2004-10-05 2006-04-20 Neuralab Limited Methods and compositions for improving recombinant protein production
CA2589017A1 (en) * 2004-12-15 2006-06-22 Neuralab Limited Amyloid beta antibodies for use in improving cognition
US8916165B2 (en) 2004-12-15 2014-12-23 Janssen Alzheimer Immunotherapy Humanized Aβ antibodies for use in improving cognition
AR051528A1 (en) * 2004-12-15 2007-01-17 Neuralab Ltd Humanized antibodies that recognize beta amyloid the peptide
WO2006081171A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
DOP2006000022A (en) * 2005-01-28 2006-08-15 Wyeth Corp stabilized liquid formulations of polypeptides
GT200600031A (en) * 2005-01-28 2006-08-29 Formulation anti beta
UY29504A1 (en) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Antibodies directed against the beta amyloid peptide and methods using the same.
EP2388274A1 (en) 2005-06-17 2011-11-23 Janssen Alzheimer Immunotherapy Methods of purifying anti A Beta antibodies
EP1951892A4 (en) * 2005-11-22 2009-01-14 Univ Pennsylvania Antibody treatment of alzheimer's and related diseases
AU2006320392B2 (en) 2005-11-30 2013-01-17 AbbVie Deutschland GmbH & Co. KG Monoclonal antibodies against amyloid beta protein and uses thereof
PT1954718E (en) 2005-11-30 2014-12-16 Abbvie Inc Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
AR057233A1 (en) 2005-12-12 2007-11-21 Hoffmann La Roche Glycosylation in the variable region
KR101591223B1 (en) * 2005-12-12 2016-02-04 에이씨 이뮨 에스.에이. A beta 1-42 specific monoclonal antibodies with therapeutic properties
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2035448A4 (en) * 2006-06-01 2010-11-03 Elan Pharm Inc Neuroactive fragments of app
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
EP2076287A2 (en) 2006-10-12 2009-07-08 Wyeth Methods and compositions with reduced opalescence
US8188046B2 (en) 2006-10-16 2012-05-29 University Of South Florida Amyloid beta peptides and methods of use
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP3239175A1 (en) 2007-01-05 2017-11-01 University of Zurich Method of providing disease-specific binding molecules and targets
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich Isolated human antibody which is capable of selectively recognizing a neoepitope of a disorder-associated protein, a polynucleotide encoding the antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, a composition comprising the antibody and methods and uses associated therewith
PT2121754E (en) 2007-01-18 2015-05-11 Lilly Co Eli Pegylated amyloid beta fab
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US7618944B2 (en) * 2007-03-01 2009-11-17 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
CN101970000A (en) * 2007-04-18 2011-02-09 杨森阿尔茨海默氏症免疫治疗公司;惠氏有限责任公司 Prevention and treatment of cerebral amyloid angiopathy
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US9656991B2 (en) 2007-04-18 2017-05-23 Probiodrug Ag Inhibitors of glutaminyl cyclase
EP2152309B1 (en) 2007-05-14 2013-07-10 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain
US8323654B2 (en) 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US7931899B2 (en) 2007-05-14 2011-04-26 Medtronic, Inc Humanized anti-amyloid beta antibodies
WO2008146854A1 (en) * 2007-05-28 2008-12-04 National Institute Of Advanced Industrial Science And Technology Paratope and epitope of anti-mortalin antibody
JP5142265B2 (en) * 2007-05-28 2013-02-13 独立行政法人産業技術総合研究所 Paratope and the epitope of the anti-mortalin antibody
KR20150055103A (en) * 2007-06-12 2015-05-20 에이씨 이뮨 에스.에이. Humanized antibodies to amyloid beta
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
NZ703668A (en) 2007-06-27 2016-07-29 Us Sec Dep Of Health And Human Services Complexes of il-15 and il-15ralpha and uses thereof
ES2498040T3 (en) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanized anti-beta
GB0718737D0 (en) * 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
EP2238166B1 (en) * 2007-10-05 2013-11-27 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
JO3076B1 (en) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap Immunotherapy regimes dependent on apoe status
JP5185946B2 (en) * 2007-10-29 2013-04-17 Taoヘルスライフファーマ株式会社 Antibody and its use
MX335965B (en) 2007-11-16 2016-01-05 Univ Rockefeller Antibodies specific for the protofibril form of beta-amyloid protein.
WO2009070648A2 (en) * 2007-11-27 2009-06-04 Medtronic, Inc. Humanized anti-amyloid beta antibodies
CA2707309A1 (en) 2007-12-18 2009-06-25 Acumen Pharmaceuticals, Inc. Novel addl receptor polypeptides, polynucleotides and host cells for recombinant production
US8414893B2 (en) * 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
EP2297209A4 (en) 2008-06-03 2012-08-01 Abbott Lab Dual variable domain immunoglobulins and uses thereof
BRPI0916366A2 (en) * 2008-07-21 2018-05-29 Probiodrug Ag diagnostic test antibody
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP2350130B1 (en) * 2008-10-31 2018-10-03 Wyeth LLC Purification of acidic proteins using ceramic hydroxyapatite chromatography
CN102272161A (en) * 2008-11-06 2011-12-07 阿雷克森制药公司 Engineered antibodies with reduced immunogenicity preparation
CA2746778C (en) 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
US8614297B2 (en) * 2008-12-22 2013-12-24 Hoffmann-La Roche Inc. Anti-idiotype antibody against an antibody against the amyloid β peptide
NZ595574A (en) 2009-04-01 2013-11-29 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use
FR2945538B1 (en) * 2009-05-12 2014-12-26 Sanofi Aventis humanized antibodies specific for the protofibrillar forms of beta-amyloid peptide.
WO2011020024A2 (en) 2009-08-13 2011-02-17 The Johns Hopkins University Methods of modulating immune function
GB0914691D0 (en) * 2009-08-21 2009-09-30 Lonza Biologics Plc Immunoglobulin variants
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
SG10201407757XA (en) * 2009-10-23 2015-01-29 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods
ES2552627T3 (en) 2009-12-11 2015-12-01 Araclón Biotech, S.L. Methods and reagents for the detection of amyloid beta peptides improved
WO2011107507A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim International Gmbh Biparatopic abeta binding polypeptides
ES2586231T3 (en) 2010-03-03 2016-10-13 Probiodrug Ag Glutaminyl cyclase inhibitors
CN102791704B (en) 2010-03-10 2015-11-25 前体生物药物股份公司 Glutaminyl cyclase (qc, ec 2.3.2.5) heterocyclic inhibitors
CA2796339A1 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
JP5945532B2 (en) 2010-04-21 2016-07-05 プロビオドルグ エージー Benzimidazole derivatives as inhibitors of glutaminyl cyclase
CN103179981B (en) 2010-07-30 2017-02-08 Ac免疫有限公司 Safe and functional humanized anti-amyloid antibodies β-
NZ606824A (en) 2010-08-02 2015-05-29 Regeneron Pharma Mice that make binding proteins comprising vl domains
JP2013537415A (en) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド Dual variable domain immunoglobulin and uses thereof
MX358739B (en) 2010-08-14 2018-09-03 Abbvie Inc Star Amyloid-beta binding proteins.
MX2013002270A (en) 2010-08-26 2013-05-14 Abbvie Inc Dual variable domain immunoglobulins and uses thereof.
NZ612643A (en) 2011-02-25 2015-06-26 Regeneron Pharma Adam6 mice
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
AU2012272790B2 (en) 2011-06-23 2016-10-06 Biogen International Neuroscience Gmbh Anti-alpha synuclein binding molecules
BR112014002713A2 (en) 2011-08-05 2017-06-13 Regeneron Pharma universal light chain humanized mice
JP2012034697A (en) * 2011-09-16 2012-02-23 Janssen Alzheimer Immunotherapy HUMANIZED ANTIBODY RECOGNIZING β-AMYLOID PEPTIDE
RU2603090C2 (en) 2011-10-17 2016-11-20 Регенерон Фармасьютикалс, Инк. Restricted immunoglobulin heavy chain mice
RU2018119366A (en) 2011-12-20 2018-11-09 Регенерон Фармасьютикалз, Инк. Mice with a humanized light chain
UY34558A (en) 2011-12-30 2013-07-31 Abbvie Inc Dual specific binding proteins directed against IL-13 and / or IL-17
SG11201406347TA (en) 2012-04-05 2014-11-27 Ac Immune Sa Humanized tau antibody
EP2841575B1 (en) 2012-04-27 2019-06-26 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
NZ703689A (en) 2012-06-12 2016-05-27 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
RU2014153675A (en) * 2012-07-03 2016-08-27 Янссен Альцгеймер Иммунотерапи Antibodies to the C-terminal and central epitopes and beta
ES2701406T3 (en) 2012-10-08 2019-02-22 Prothena Biosciences Ltd Antibodies that recognize alpha-synuclein
PE11792015A1 (en) 2012-11-01 2015-09-12 Abbvie Inc Dual variable domain immunoglobulins anti-vegf / Dll4 and uses thereof
SG11201505383UA (en) 2013-02-20 2015-08-28 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
MX2015013166A (en) 2013-03-15 2015-12-11 Abbvie Inc Dual specific binding proteins directed against il-1 beta and il-17.
WO2015004632A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize iapp
WO2015004633A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize islet-amyloid polypeptide (iapp)
WO2015136471A1 (en) 2014-03-12 2015-09-17 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
US10059761B2 (en) 2014-03-12 2018-08-28 Prothena Biosciences Limited Anti-Laminin4 antibodies specific for LG4-5
US20170174777A1 (en) 2014-04-08 2017-06-22 Prothena Bioscience Limited Blood-Brain Barrier Shuttles Containing Antibodies Recognizing Alpha-Synuclein
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2015191934A2 (en) 2014-06-11 2015-12-17 Abbvie Inc. Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases
JP2018505652A (en) 2014-11-19 2018-03-01 ジェネンテック, インコーポレイテッド Anti-transferrin receptor / anti bace1 multispecific antibodies and methods of use
EP3221362A1 (en) 2014-11-19 2017-09-27 F.Hoffmann-La Roche Ag Anti-transferrin receptor antibodies and methods of use
SG11201703750XA (en) 2014-12-10 2017-06-29 Genentech Inc Blood brain barrier receptor antibodies and methods of use
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
WO2018007923A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
TW201632554A (en) 2015-01-28 2016-09-16 Prothena Biosciences Ltd Anti-transthyretin antibodies
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
WO2018007924A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
TW201636372A (en) 2015-01-28 2016-10-16 Prothena Biosciences Ltd Anti-transthyretin antibodies
TW201636371A (en) 2015-01-28 2016-10-16 Prothena Biosciences Ltd Anti-transthyretin antibodies
TW201710286A (en) 2015-06-15 2017-03-16 Abbvie Inc Binding proteins against VEGF, PDGF, and/or their receptors
AU2016280102A1 (en) 2015-06-16 2017-12-07 Genentech, Inc. Humanized and affinity matured antibodies to FcRH5 and methods of use
AR106189A1 (en) 2015-10-02 2017-12-20 F Hoffmann-La Roche Ag Bispecific antibodies against human Ab AND human transferrin receptor and methods of use
MX2018013384A (en) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Antibodies recognizing tau.
CA3022765A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Antibodies recognizing tau
EP3461819A1 (en) 2017-09-29 2019-04-03 Probiodrug AG Inhibitors of glutaminyl cyclase

Family Cites Families (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
CH652145A5 (en) 1982-01-22 1985-10-31 Sandoz Ag METHOD FOR IN VITRO PRODUCTION OF HYBRID OMEN WHAT human monoclonal antibodies GENERATE.
JPS6215722B2 (en) * 1982-05-31 1987-04-09 Ngk Insulators Ltd
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4713366A (en) 1985-12-04 1987-12-15 The Ohio State University Research Foundation Antigenic modification of polypeptides
US5096706A (en) 1986-03-25 1992-03-17 National Research Development Corporation Antigen-based treatment for adiposity
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5278049A (en) 1986-06-03 1994-01-11 Incyte Pharmaceuticals, Inc. Recombinant molecule encoding human protease nexin
US5231170A (en) 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5187153A (en) 1986-11-17 1993-02-16 Scios Nova Inc. Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US5220013A (en) 1986-11-17 1993-06-15 Scios Nova Inc. DNA sequence useful for the detection of Alzheimer's disease
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US4912206A (en) 1987-02-26 1990-03-27 The United States Of America As Represented By The Department Of Health And Human Services CDNA clone encoding brain amyloid of alzheimer's disease
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5645820A (en) 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571499A (en) 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5641474A (en) 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5571500A (en) 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5869054A (en) 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5849298A (en) 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5231000A (en) 1987-10-08 1993-07-27 The Mclean Hospital Antibodies to A4 amyloid peptide
US5576184A (en) 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5227159A (en) * 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5089603A (en) * 1989-06-21 1992-02-18 Tanox Biosystems, Inc. Antigenic epitopes present on membrane-bound but not secreted iga
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
DE69133566D1 (en) 1990-01-12 2007-04-26 Amgen Fremont Inc Formation of xenogenic antibodies
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
JPH05506990A (en) 1990-04-24 1993-10-14
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
CA2081482C (en) 1990-04-27 2000-11-21 Ellis L. Kline Method and composition for treatment of central nervous system disease states associated with abnormal amyloid beta protein molecular organization
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5593970A (en) 1990-06-11 1997-01-14 Biochem Pharma Inc. Heterocyclic anthracycline analogs
CA2085127C (en) 1990-06-15 2002-12-10 Barbara Cordell Transgenic non-human mammal displaying the amyloid-forming pathology of alzheimer's disease
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (en) 1990-07-10 2000-02-16 Medical Res Council Procedures for producing members of specific binding partners.
DE69230142T2 (en) 1991-05-15 2000-03-09 Cambridge Antibody Tech A process for the preparation of specific binding pair members
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
US5780587A (en) 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
DK0546073T3 (en) 1990-08-29 1998-02-02 Genpharm Int Making and using transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5702906A (en) 1990-09-25 1997-12-30 Genentech, Inc. Antibodies to neurotrophic factor-4 (NT-4)
WO1992013069A1 (en) 1991-01-21 1992-08-06 Imperial College Of Science, Technology & Medicine Test and model for alzheimer's disease
US5192753A (en) 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
US5245015A (en) 1991-04-26 1993-09-14 Tanox Biosystems, Inc. Monoclonal antibodies which neutralize HIV-1 through reaction with a conformational epitope in vitro
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (en) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and derivatives chemical immuno including immotoxines
US5434050A (en) 1991-08-13 1995-07-18 Regents Of The University Of Minnesota Labelled β-amyloid peptide and methods of screening for Alzheimer's disease
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council Procedures for the production of humanized antibodies.
US5837268A (en) 1991-10-16 1998-11-17 University Of Saskatchewan GnRH-leukotoxin chimeras
US5679348A (en) 1992-02-03 1997-10-21 Cedars-Sinai Medical Center Immunotherapy for recurrent HSV infections
ES2204900T3 (en) 1992-02-11 2004-05-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine inmuinogena structure dual vector.
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5441870A (en) 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5605811A (en) 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
US5851787A (en) 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
EP0652758B1 (en) * 1992-06-18 2000-01-05 The President And Fellows Of Harvard College Diphtheria toxin vaccines
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
AU667578B2 (en) 1992-08-27 1996-03-28 Deakin Research Limited Retro-, inverso-, and retro-inverso synthetic peptide analogues
US5958883A (en) 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
JP3720353B2 (en) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル Multivalent and multispecific binding proteins, their preparation and use
US5750349A (en) 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
US5955317A (en) 1993-01-25 1999-09-21 Takeda Chemical Industries, Ltd. Antibodies to β-amyloids or their derivatives and use thereof
DE614989T1 (en) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung A process for ligand binding in vivo selection of proteins.
JPH08508252A (en) * 1993-03-17 1996-09-03 アメリカ合衆国 Immunogenic chimeric containing a nucleic acid sequence encoding at least one other peptide endoplasmic reticulum signal sequence peptide, and used in the treatment of vaccines and diseases of the chimeric
DE69428136D1 (en) 1993-03-23 2001-10-04 Smithkline Beecham Biolog 3-0 Deazylierte monophosphoryl lipid A containing vaccine compositions
IT1270939B (en) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio A process for the preparation of immunogens and diagnostic reagents, and immunogens and diagnostic reagents so 'obtainable.
US5464823A (en) 1993-07-20 1995-11-07 The Regents Of The University Of California Mammalian antibiotic peptides
EP0714308A4 (en) 1993-08-26 1998-07-29 Univ California Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides
US5652334A (en) 1993-09-08 1997-07-29 City Of Hope Method for design of substances that enhance memory and improve the quality of life
US5385887A (en) * 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
DK0735893T3 (en) 1993-09-14 2009-03-09 Pharmexa Inc PAN DR-binding peptides for strengthening the immune response
US5470951A (en) 1993-09-29 1995-11-28 City Of Hope Peptides for antagonizing the effects of amyloid βprotein
US5858981A (en) * 1993-09-30 1999-01-12 University Of Pennsylvania Method of inhibiting phagocytosis
JP3504963B2 (en) * 1993-10-22 2004-03-08 アサヒビール株式会社 DNA fragment encoding the amino acid sequence of the anti-human high affinity IgE receptor monoclonal antibody
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5434170A (en) 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
DE69533583D1 (en) 1994-01-27 2004-11-04 Univ Minnesota Southeast Non-human, transgenic mammals with evolving neurological disease
JPH09511492A (en) 1994-02-03 1997-11-18 ザ ピコワー インスティテュート フォア メディカル リサーチ Compositions and methods for forward glycosylation endproducts mediated modulation of amyloidosis
CA2122573A1 (en) * 1994-04-13 1995-10-14 John M. Pratt Dynamic electronic mail facility for applications executing in an integrated operating environment
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5622701A (en) 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US6417178B1 (en) * 1994-07-19 2002-07-09 University Of Pittsburgh Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
US6114133A (en) 1994-11-14 2000-09-05 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5688651A (en) 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
AT216590T (en) * 1995-02-06 2002-05-15 Genetics Inst Drug formulations for il-12
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
US5624937A (en) * 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
DE69621607T2 (en) 1995-03-14 2003-01-02 Praecis Pharm Inc CONNECTIONS aggregation MODULATING EFFECT ON THE PROTEIN amyloid
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
US5817626A (en) 1995-03-14 1998-10-06 Praecis Pharmaceuticals Incorporated Modulators of beta-amyloid peptide aggregation
US5854215A (en) 1995-03-14 1998-12-29 Praecis Pharmaceuticals Incorporated Modulators of β-amyloid peptide aggregation
US6303567B1 (en) 1995-03-14 2001-10-16 Praecis Pharmaceuticals, Inc . Modulators of β-amyloid peptide aggregation comprising D-amino acids
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
AT214603T (en) 1995-06-30 2002-04-15 American Cyanamid Co compositions stable macrolide and macrolide imptstoff-
AU6898996A (en) 1995-08-21 1997-03-12 Cytrx Corporation Compositions and methods for growth promotion
WO1997010505A1 (en) 1995-09-14 1997-03-20 The Regents Of The University Of California ANTIBODIES SPECIFIC FOR NATIVE PrP?Sc¿
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US5750361A (en) 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
AU1072897A (en) 1995-12-12 1997-07-03 Karolinska Innovations Ab Peptide binding the klvff-sequence of amyloid beta
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
EP0787764B1 (en) * 1996-02-03 2003-04-09 Mitsubishi Gas Chemical Company, Inc. Oxygen-absorbing resin composition and packing material, multi-layered packing material, package and packing method using the same
US6150091A (en) 1996-03-06 2000-11-21 Baylor College Of Medicine Direct molecular diagnosis of Friedreich ataxia
US6284533B1 (en) 1996-05-01 2001-09-04 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
TW373320B (en) * 1996-05-27 1999-11-01 United Microelectronics Corporaiton Structure and production method of capacitor of dynamic RAM
US6057367A (en) 1996-08-30 2000-05-02 Duke University Manipulating nitrosative stress to kill pathologic microbes, pathologic helminths and pathologically proliferating cells or to upregulate nitrosative stress defenses
US6022859A (en) 1996-11-15 2000-02-08 Wisconsin Alumni Research Foundation Inhibitors of β-amyloid toxicity
US6218506B1 (en) 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US5798102A (en) 1997-03-04 1998-08-25 Milkhaus Laboratory, Inc. Treatment of cardiomyopathy
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
US20020086847A1 (en) * 1997-04-09 2002-07-04 Mindset Biopharmaceuticals (Usa) Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US6787319B2 (en) * 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
CA2301575C (en) * 1997-05-20 2003-12-23 Heather L. Davis Vectors and methods for immunization or therapeutic protocols
US6175057B1 (en) * 1997-10-08 2001-01-16 The Regents Of The University Of California Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6743427B1 (en) * 1997-12-02 2004-06-01 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6913745B1 (en) * 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6710226B1 (en) * 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US20050059591A1 (en) * 1998-04-07 2005-03-17 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6528624B1 (en) * 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
DE69920897T2 (en) * 1998-04-28 2005-10-13 Smithkline Beecham Corp. Monoclonal antibodies with reduced immunogenicity
US20030147882A1 (en) * 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6727349B1 (en) * 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
EP1150688A4 (en) * 1998-10-19 2004-06-16 Yeda Res & Dev Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens
US6441870B1 (en) * 1998-12-22 2002-08-27 Gateway, Inc. Automatic gamma correction for multiple video sources
CA2376693C (en) * 1999-06-16 2013-09-10 Boston Biomedical Research Institute Immunological control of .beta.-amyloid levels in vivo
US6264335B1 (en) * 1999-06-25 2001-07-24 James C. Bass, Sr. Light-reflective marking clip
US6756378B2 (en) * 1999-06-30 2004-06-29 Pharmacopeia Drug Discovery, Inc. VLA-4 inhibitor compounds
US6294171B2 (en) 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US20020094335A1 (en) * 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
US6399314B1 (en) 1999-12-29 2002-06-04 American Cyanamid Company Methods of detection of amyloidogenic proteins
DE1257584T1 (en) * 2000-02-24 2003-05-28 Univ St Louis uncheck the amyloid-beta peptide humanized antibodies,
AU2001274873B2 (en) * 2000-05-22 2006-10-05 New York University Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits
US20020009445A1 (en) * 2000-07-12 2002-01-24 Yansheng Du Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
PE05742002A1 (en) * 2000-12-06 2002-07-02 Wyeth Corp Humanized antibodies that recognize beta amyloid the peptide
AU2002257162A1 (en) * 2001-04-30 2002-11-11 Eli Lilly And Company Humanized antibodies
WO2002088306A2 (en) * 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US6733547B2 (en) * 2001-12-10 2004-05-11 Delphi Technologies, Inc. Method of making a paste composition for lead acid battery
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
TWI306458B (en) * 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide

Also Published As

Publication number Publication date
EA010469B1 (en) 2008-08-29
UY27062A1 (en) 2002-07-31
AU2002225921B2 (en) 2008-07-10
KR100996936B1 (en) 2010-11-29
CA2430772A1 (en) 2002-06-13
HK1070904A1 (en) 2009-12-18
NO20032549L (en) 2003-08-05
TWI255272B (en) 2006-05-21
EP2045267A3 (en) 2010-12-08
DE60136651D1 (en) 2009-01-02
EA200602015A1 (en) 2007-02-27
AT414719T (en) 2008-12-15
CN100448893C (en) 2009-01-07
US20030165496A1 (en) 2003-09-04
HRP20030547A8 (en) 2010-05-31
PT1358213E (en) 2009-01-28
JP4944149B2 (en) 2012-05-30
CA2430772C (en) 2010-11-30
ES2317953T3 (en) 2009-05-01
HU229681B1 (en) 2014-04-28
BG66292B1 (en) 2013-02-28
SK8502003A3 (en) 2004-03-02
WO2002046237A3 (en) 2003-09-04
JP2012147797A (en) 2012-08-09
JP5059541B2 (en) 2012-10-24
IS6848A (en) 2003-06-16
CN101081869A (en) 2007-12-05
BG107850A (en) 2004-02-27
NZ526813A (en) 2006-10-27
PL211761B1 (en) 2012-06-29
NZ546620A (en) 2008-04-30
CZ20031601A3 (en) 2003-12-17
EA011450B1 (en) 2009-02-27
JP2005500808A (en) 2005-01-13
ZA200305169B (en) 2004-07-09
HU0302589A3 (en) 2008-03-28
UA87093C2 (en) 2009-06-25
KR20070004139A (en) 2007-01-05
MY162171A (en) 2017-05-31
EE200300264A (en) 2003-10-15
WO2002046237A2 (en) 2002-06-13
US7189819B2 (en) 2007-03-13
EP1358213A2 (en) 2003-11-05
EE05309B1 (en) 2010-06-15
EA200300637A1 (en) 2004-06-24
IL156030D0 (en) 2003-12-23
SI1358213T1 (en) 2009-04-30
JP2008099694A (en) 2008-05-01
PL366341A1 (en) 2005-01-24
JP2008073051A (en) 2008-04-03
NZ546621A (en) 2008-09-26
NO20032549D0 (en) 2003-06-05
ECSP034685A (en) 2003-09-24
US7582733B2 (en) 2009-09-01
JP2008073052A (en) 2008-04-03
GEP20084339B (en) 2008-03-25
EP1358213B1 (en) 2008-11-19
AU2592102A (en) 2002-06-18
HRP20030547A2 (en) 2005-06-30
SK288209B6 (en) 2014-07-02
IS2620B (en) 2010-05-15
MXPA03005048A (en) 2004-09-10
BR0115978A (en) 2005-05-03
JP2009159981A (en) 2009-07-23
CN1541225A (en) 2004-10-27
EP2045267A2 (en) 2009-04-08
KR20030066695A (en) 2003-08-09
US20050009150A1 (en) 2005-01-13
CN101081867A (en) 2007-12-05
JP4166569B2 (en) 2008-10-15
IL156030A (en) 2009-06-15
CY1108740T1 (en) 2014-04-09
DK1358213T3 (en) 2009-03-02
HU0302589A2 (en) 2003-10-28
CN101081868A (en) 2007-12-05
AR035402A1 (en) 2004-05-26
MY163362A (en) 2017-09-15
NO339290B1 (en) 2016-11-21
AU2002225921B8 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
Bard et al. Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology
RU2461571C2 (en) Il-12/p40 binding proteins
ES2656359T3 (en) anti-NKG2A antibodies and uses thereof
IL165193D0 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
BR0210405A (en) isolated human monoclonal antibody, hybridoma, transfectoma, non-transgenic human animal, bispecific molecule composition immunotoxin expression vector and methods for producing an antibody to inhibit the growth of a cell expressing EGFR, for inducing cytolysis of a cell expressing EGFR, for treating or preventing a disease mediated by EGFR expression and the presence of EGFR antigen, or a cell expressing EGFR in a sample
EA201492217A1 (en) Human monoclonal antibodies against cd20
PA8639701A1 (en) Antibody composition her2
CY1117756T1 (en) Chimeric hybrids MONOMER-DIMERIC IMMUNOGLOBULIN
PE03172007A1 (en) Sclerostin binding agents or fragments sclerostin
RU2008122341A (en) Application of the complement pathway inhibitors for treating eye diseases
EA200800355A1 (en) Neutralizing antibodies against human b7rp1
NO20052220L (en) The method feeder for treating Alzheimer's disease using antibodies directed against amyloid beta-peptide and compositions thereof
PE16252008A1 (en) Antigen binding protein receptor to IL-17
CO6251322A2 (en) Polypeptides antibody variable domains and antagonists
NZ566395A (en) Human monoclonal antibodies to CD70
EA200100780A1 (en) Receptor antagonists and tweak tweak and their use for treating immunological diseases
EA200600275A1 (en) The cytotoxic conjugate, specific in relation to the CA6 antigen, and methods of application
EA200501560A1 (en) Prevention and treatment of amyloidogenic disease
CR20140394A (en) monoclonal antibody
EA200500497A2 (en) ANTIBODIES TO IFN-γ AND METHOD FOR PRODUCING AND USE THEREOF
JP2017505125A (en) Human antibodies against pd-1
MXPA01013186A (en) Prion protein peptides and uses thereof.
NO20083793L (en) Antibodies to amyloid-beta peptide
UA89350C2 (en) Humanized antibody that specifically binds human cd20
SA696B1 (en) Protein Chlamydia chlamydia protein sequences of religion and uses

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed